TD2 and Deep 6 AI Announce Partnership to Accelerate Oncology Clinical Trial Recruitment
Artificial intelligence used to identify potential clinical trial participants in minutes
SCOTTSDALE, Ariz. and PASADENA, Calif. (May 31, 2017) – Translational Drug Development (TD2) and Deep 6 AI announced today a formal agreement to work together in the fields of oncology and fibrosis to rapidly match eligible patients with appropriate clinical trials.
The partnership grants TD2—an oncology development organization—access to cutting-edge artificial intelligence provided by Deep 6 AI, a company dedicated to finding patients for clinical trials. With the ability to analyze all structured and unstructured clinical data, including physician notes and pathology and genomic reports, Deep 6 AI’s system expedites the process of matching patients with new drug trials—finding suitable participants in minutes rather than the months it takes to manually review patient records.
“Partnering with Deep 6 AI allows TD2 to provide patients with rapid access to the newest, most advanced medicines. Our sponsor companies benefit from more timely study enrollment and patient identification that precisely matches study protocols, increasing the opportunity to demonstrate clinical activity for new medicines earlier in development,” said Stephen Gately, CEO of TD2.
This new approach allows TD2 to continuously monitor the number of eligible patients with specific cancers who are available to participate in a clinical study; identify patient populations that are rare in incidence or genomic context to define trial and regulatory opportunities; and develop dynamic protocols with inclusion/exclusion criteria based on real-time patient data.
“The partnership will advance our shared mission of getting cutting-edge treatments to patients more quickly,” said Wout Brusselaers, CEO of Deep 6 AI. “We’re thrilled to offer TD2 the ability to mine real-time patient data to guide trial feasibility and design, site selection and patient enrollment. Together we will significantly accelerate medical research.”
Over the coming months, TD2 and Deep 6 AI will establish a network of the top Phase 1 and 2 sites in oncology clinical trials to expand site and industry access to patient electronic data.
Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.td2inc.com. TD2 is a portfolio company of ORIX USA Corporation.
ABOUT DEEP 6 AI
Deep 6 AI finds patients for clinical trials in minutes. Using artificial intelligence and natural language processing on medical records, Deep 6 AI accelerates patient recruitment exponentially, getting life-saving cures to patients more quickly. Deep 6 AI also helps sponsors and CROs with better trial feasibility design, site selection, real-time analysis of study results, and improved trial response rates, from selecting better-matching trial subjects.
Deep 6 AI is a Techstars, StartX and Healthbox alum and is currently in use by leading hospitals, such as Cedars-Sinai Medical Center, research institutes and CROs. The company was founded in 2013 and is based in Pasadena, CA. Learn more at https://deep6.ai
Tara Franks, TD2
Linda Souza, Deep 6 AI